Assessing real-world effects of a low nicotine standard on smoked tobacco in New Zealand
Official title: Assessing the real-world impact of a low nicotine product standard for smoked tobacco in New Zealand
Funded at Wake Forest University Health Sciences · NIH-11455247 · Data updated 2026-11-12
This study follows adults who smoke daily to see how a policy that lowers nicotine in all smoked tobacco products could change their smoking behavior and health in real life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $193,987 |
| NIH project number | 3R01DA058264-04S3 |
| Project ID | NIH-11455247 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21+ who smoke cigarettes or other combusted tobacco products daily or almost daily and are willing to participate long-term.
✕Less likely to help
Individuals who do not smoke or who are unable to participate for the full follow-up period may not benefit from the study results.
What this research studies
Researchers will recruit about 1,500 adults who smoke daily and track them over about 3.5 years, using online surveys, biomarker tests, physiological checks, interviews, and medical records. They will compare data from 1.5 years before and 1 year after a potential low-nicotine product standard is implemented to understand real-world impacts. The study aims to reveal how reduced nicotine in all smoked products affects smoking habits, exposure to harmful substances, and overall well-being in everyday settings.
Why it matters
Potential benefit: If successful, findings could inform policies that help reduce smoking, improve health, and support better quit efforts.
How similar studies have gone: Previous clinical trials suggested benefits of low-nicotine cigarettes, but this study adds real-world evidence with a longer follow-up and diverse data sources.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Denlinger-Apte, Rachel — Wake Forest University Health Sciences
- Study coordinator: Denlinger-Apte, Rachel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.